

MMGL MOLECULAR GENETICS REQUISITION

		100				IDNI				
Experti:	se Delivered	Personally		Client	Patient Reg or M	IRN:				
Michigan Medicine – University of Michigan Department of Pathology – MLabs				Patient Name:	Last	First	MI			
UH 2F361 • 1500 E. Medical Center Driv			/e	Ward	Birthdate:		Gender: OM	1 OF		
Ann Arbor, MI 48109-5054 734-936-2598 • 800-862-7284					Ondering Death		First	NIDI#		
www.mlabs.umich.edu				Ordering Doctor	::Last	First	NPI#			
Patient	Address		City	Stat	te ZIP	Home P	hone #			
Policy F	Holders Name		Primary Ins	surance (Card Name)) Prima	ry Policy/Contract #	Primary Group	p # Policy Holders	DOB	
Policy F	olicy Holders Name Secondary		Insurance (Card Name) Seco		ndary Policy/Contrac	ct # Secondary Gro	Secondary Group # Policy Holders DOB			
Bill To: ☐ Client/Referring Institution ☐ Patient			☐ Patient/	Insurance If patient or insurance information is not included or attached to this form, your facility will be billed. For Medicare patients classified as a hospital inpatient or						
	☐ Medicare = ☐ In Patient on DOS ☐ Out Patien									
					rior authorization for payment. To obtain Blue Care Network (BCN) prior authorization call Joint Venture Hospital 1979. For all other carriers contact the plan directly.					
		☐ Prior authorization								
								<u> </u>		
Informe	ed Consent:	obtain this consent.	If desired, a	chigan law for presymptomatic or predictive genetic tests. It is the responsibility of the physician (or designee) to UMHS Request and Consent for Genetic Testing form can be obtained by contacting MLabs at 800-862-7284 or 'files/pdfs/PCI-MMGL_InformedConsent.pdf.						
		☐ Informed consent				'				
ICD-10	CODES				ICD-1	0 Codes are required fo	or billing. When ordering tests	for which reimbursement will	be sought,	
					order	only tests that are med	dically necessary for the diagno	osis and treatment of the patie	ent.	
REFERRING PHYSICIAN TO BE CONTACTED WI Referring Physician Referring				TH RESULTS AND/OR QUESTION Institution		ONS	Phone	Fax		
Address				City	/	State	ZIP	Country		
							the patient as required by aped to the ordering physician.	oplicable state or federal laws	for each	
PATIEN	NT HISTOR	Y/DIAGNOSIS								
			Collecti	on Date:	Time:	Oam Opm) Foot	note: Case/Accn #			
All test	s include natho	ologist interpretation a	at a senarate	additional charge						
	•	nogist interpretation a	it a separate				Lamon			
MICROARRAY Chromosomal Microarray Analysis (SNPM1)				e Sequencing (SHNK		OTHER ATP7R Gone Sequencing (ATP7R)				
☐ Chromosomal Microarray Analysis (SNPM1)				e Sequencing (SHNK		☐ ATP7B Gene Sequencing (ATP7B) ☐ BTD Gene Sequencing (BTDS)				
AUTISM / INTELLECTUAL DISABILITY Autism / ID Panel reflex to all Tiers (ALIS)			☐ SLC9A6 Gene Sequencing (SLC9A)				☐ CHD7 Gene Sequencing (CHD7S)			
☐ Autism / ID Panel reflex to all Tiers (AUS)			☐ TCF4 (Pitt-Hopkins Syndrome) Gene			'	☐ DiGeorge Panel (DIGP1) includes reflex to			
☐ Autism / ID Panel Tier 1 (AUS1) includes SNPM1, FRXFA, PWSMP			Sequencing (TCF4S) UBE3A Gene Sequencing (UBE3A)			Chromosomal Microarray				
☐ Autism / ID Panel Tier 2 (AUS2)						☐ GAA Gene Sequencing (GAAS)				
includes MECS, PTENS, MECD, PTED				HEARING LOSS		-:- (CV2(C)	MSH2	9 (0, 1, 10)		
☐ Autism / ID Panel Tier 3 (AUS3)					tin 26) Mutation Anal t to GJB6 (Connexin		☐ Gene Sequencing (MSH2S)			
includes UBE3A, MBD5S, NLGN3, NLGN4, SHNK2, SHNK3, SLC9A, TCF4S, CDKL5			☐ GJB2 (Connex	in 26) Targeted Sequ	·	☐ MSH2 Targeted Sequencing Familial (MSH2F)				
☐ CDKL5 Gene Sequencing (CDKL5)			Familial (CX26			☐ NF1 Gene Sequencing (NF1S)				
☐ GDI1 Gene Sequencing (GDI1)			1	m Syndrome) Gene S		□ NOGGIN Gene Sequencing (NOGS)				
☐ Fragile X Syndrome Mutation (FRXFA)			☐ SLC17A8 6320	C>T (A21V) Mutation	Detection (SLC17)	☐ Ornithine Transcarbamylase Deficiency (OTC) Gene Sequencing (OTCS)				
☐ MBD5 Gene Sequencing (MBD5S)			NOONAN SYNI			☐ PAI1 (SERPINE1) Mutation Detection (PAI1M)				
MECP2 (Rett Syndrome)				-	ome reflex to all Tier	s (NSSTS)	☐ SERPINE1 Gene Sequencing (SERPS)			
	•	•			ome Tier 1 (NSST1)	NC4				
☐ Gene Sequencing (MECS) ☐ Deletion/Duplication (MECD)				l11 exons 3, 8, 13, SC , 16, RAF1 exons 7, 1		☐ SETBP1 Mutation Detection (SETM) ☐ SLC7A7 Gene Sequencing (SLC7A)				
☐ Targeted Sequencing Familial (MECF)				ome Tier 2 (NSST2)	., .,	☐ SMN1&2 Deletion / Copy Number Analysis (SMN1D)				
☐ MEF2C Gene Sequencing (MEFS)			-	111 exons 1, 2, 4-7, 9	12, 14, 15	The state of the s				
☐ NLGN3 Gene Sequencing (NLGN3)				ome Tier 3 (NSST3)	,,	☐ Gene Sequencing (TP53S)				
□ NLGN4X Gene Sequencing (NLGN4)			,	exons 1, 2, 4, 5, 7-9,	11-15, 17-23,	□ Deletion/Duplication Analysis (TP53D)				
☐ Prader-Willi / Angelman Syndrome by PCR (PWSMP)			KRAS2 exons 2-6			Other:				
PTEN Hamartoma Tumor Syndrome (PHTS)				☐ PTPN11 Gene Sequencing in Inherited						
☐ Gene Sequencing (PTENS)			Disorders (PTF	PNS)						
☐ Deletion/Duplication (PTED)			☐ SOS1 Gene Se	equencing in Inherite	d Disorders (SOS1S)					
☐ Targeted Sequencing Familial (PTENF)			☐ KRAS Gene Se	equencing in Inherite	d Disorders (RASKS)					
☐ PTEN Promoter Sequencing										

Specimen Type for all assays: Peripheral Blood, 5-10 mL Lavender/EDTA tube

For technical questions, call lab (734) 615-2429